

## Distribution partnership agreements, 8/15

**EDP Biotech has entered into distribution agreements with more than 25 distribution channel partners** throughout Europe, Asia, and South America. EDP plans a multiphase rollout of ColoMarker, a blood test that aids in the detection of early stage colorectal cancer, in 2015 to gain experience and data in conjunction with key opinion leaders and distributor partners.

ColoMarker enables clinicians to use a simple blood sample to quickly detect CA11-19, a biomarker that is highly correlated to early stages of colorectal cancer. ColoMarker has been tested in multiple sites with a large number of samples having both known and unknown stages of colorectal cancer (stages I-IV). In a recent multicenter study, clinically verified ColoMarker results demonstrated a sensitivity approaching 100 percent for early stage colorectal cancer (stages I-II) and an overall cancer detection rate of approximately 98 percent with a specificity of 84 percent.

[\*\*EDP Biotech\*\*](#), 865-246-0514